Edwards Lifesciences raises 2026 sales and TAVR growth guidance
Edwards Lifesciences increased its full-year 2026 sales growth rate guidance to 10% to 11% from 9% to 11%, TAVR product group sales growth guidance to 8% to 9% from 7%…
Company
SEC filing news and material events for Edwards Lifesciences Corp, briefed from primary-source filings.
1 story
Edwards Lifesciences increased its full-year 2026 sales growth rate guidance to 10% to 11% from 9% to 11%, TAVR product group sales growth guidance to 8% to 9% from 7%…